Immunocompromised Swiss Cohorts Based Trial Platform

PHASE3CompletedINTERVENTIONAL
Enrollment

610

Participants

Timeline

Start Date

April 19, 2021

Primary Completion Date

September 23, 2023

Study Completion Date

September 23, 2023

Conditions
Immunocompromised Patients
Interventions
BIOLOGICAL

Moderna COVID-19 Vaccine, mRNA-1273 (100 μg)

intramuscular injection, proposed as a series of two doses (0.5 mL each), dosing is 100 microgram on day 0 and day 28

BIOLOGICAL

Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®)

intramuscular injection, proposed dosing is 30 microgram of the diluted vaccine solution (0.3 mL each) on day 0 and day 21

Trial Locations (4)

1011

University Hospital Lausanne CHUV, Lausanne

3010

University Hospital Bern, Bern

4031

University Hospital Basel, Basel

8091

University Hospital Zurich, Zurich

All Listed Sponsors
collaborator

Swiss National Science Foundation

OTHER

collaborator

ModernaTX, Inc.

INDUSTRY

lead

University Hospital, Basel, Switzerland

OTHER